Insights

Innovative Neurotherapies Neurocentria is pioneering a new class of treatments targeting novel molecular pathways for neurodegenerative and neuropsychiatric disorders, which addresses a significant gap in current therapies. This positions the company to be a leader in cutting-edge brain health solutions, offering opportunities for partnerships and licensing with healthcare providers and research institutions.

Clinical Development Milestones With multiple drug candidates progressing through pivotal Phase IIb/III trials for ADHD, Alzheimer’s, and depression, Neurocentria is at a stage where successful outcomes can lead to accelerated market entry, creating sales opportunities for distribution partners and clinicians seeking innovative treatment options.

Recent Product Launch The launch of MMFS-01, a magnesium-based supplement, opens up additional revenue channels in the dietary supplement and wellness markets, appealing to consumers and healthcare providers interested in adjunct therapies for cognitive health and neuroinflammation.

Funding and Growth Potential Although specific funding details are not disclosed, the company's revenue range of 25 to 50 million dollars suggests a viable growth trajectory. Targeted outreach to biotech investors and healthcare organizations could facilitate strategic alliances and expanded market access for their pipeline products.

Technological Edge Utilizing advanced digital infrastructure such as Google Cloud CDN and data analytics tools, Neurocentria is positioned to support scalable clinical trial management and data-driven marketing strategies, enabling efficient engagement with key stakeholders in the neurohealth ecosystem.

Similar companies to Neurocentria, Inc.

Neurocentria, Inc. Tech Stack

Neurocentria, Inc. uses 8 technology products and services including Google Cloud CDN, Wix eCommerce, Sirvoy, and more. Explore Neurocentria, Inc.'s tech stack below.

  • Google Cloud CDN
    Content Delivery Network
  • Wix eCommerce
    E-commerce
  • Sirvoy
    Hotel Management
  • React
    Javascript Frameworks
  • Lodash
    Javascript Libraries
  • HSTS
    Security
  • reCAPTCHA
    Security
  • Google Analytics
    Web Analytics

Neurocentria, Inc.'s Email Address Formats

Neurocentria, Inc. uses at least 1 format(s):
Neurocentria, Inc. Email FormatsExamplePercentage
FLast@neurocentria.comJDoe@neurocentria.com
50%
FLast@neurocentria.comJDoe@neurocentria.com
50%

Frequently Asked Questions

What is Neurocentria, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Neurocentria, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Neurocentria, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Neurocentria, Inc.'s official website is neurocentria.com and has social profiles on LinkedIn.

What is Neurocentria, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Neurocentria, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Neurocentria, Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, Neurocentria, Inc. has approximately 13 employees across 1 continents, including North America. Key team members include Sr Director Cmc: W. Z.Clinical Trial Manager/ Sponsor Feasibility Manager: M. B.. Explore Neurocentria, Inc.'s employee directory with LeadIQ.

What industry does Neurocentria, Inc. belong to?

Minus sign iconPlus sign icon
Neurocentria, Inc. operates in the Biotechnology Research industry.

What technology does Neurocentria, Inc. use?

Minus sign iconPlus sign icon
Neurocentria, Inc.'s tech stack includes Google Cloud CDNWix eCommerceSirvoyReactLodashHSTSreCAPTCHAGoogle Analytics.

What is Neurocentria, Inc.'s email format?

Minus sign iconPlus sign icon
Neurocentria, Inc.'s email format typically follows the pattern of FLast@neurocentria.com. Find more Neurocentria, Inc. email formats with LeadIQ.

When was Neurocentria, Inc. founded?

Minus sign iconPlus sign icon
Neurocentria, Inc. was founded in 2005.

Neurocentria, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Neurocentria is a late-stage biotechnology company dedicated to discovering and developing novel treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression and Alzheimer’s disease. Since 2005, our team has been innovating breakthrough therapies to address the pathophysiology of these disorders, prevent their progression or even reverse their course, reduce symptoms and improve patients’ performance and quality of life.

Currently available treatments for these disorders are acting on classical targets identified decades ago, especially for ADHD and depression, with no new approaches introduced during this time. And, too often, patients endure just as much from the side effects of their medications. 

Our novel therapy, NRCT-101SR, is a new class of treatment for neurological disorders, developed to act on new molecular targets. In preclinical studies, NRCT-101, the API of NRCT-101SR, increased synapse density and plasticity, improving synaptic function. Importantly, NRCT-101 enhanced cognitive function and improved emotional regulation in young animals, and prevented synaptic loss and alleviated cognitive impairment in aged animals. Similar effects of NRCT-101 were seen in models of neuroinflammation.

In early-stage human clinical trials, NRCT-101 was shown to:

➫ Improve mood status in 3-7 days versus the several weeks it takes for most medications

➫ Address ADHD symptoms without imposing side effects 

➫ Improve cognition for adults with late-life depression, anxiety, ADHD and Alzheimer’s & Alzheimer’s-like symptoms

➫ Produce no negative side effects

The FDA recently approved our drug candidate for a pivotal Phase IIb/III human trial for adults with ADHD, a Phase IIb human trial in Alzheimer’s, and we are working on a phase IIb/III human trial in adults with major depressive disorder.

We are fully committed to developing novel brain health therapies that are safe, improve people’s conditions and promote healthy communities.

Section iconCompany Overview

Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2005
Employees
11-50

Section iconFunding & Financials

  • $25M$50M

    Neurocentria, Inc.'s revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $25M$50M

    Neurocentria, Inc.'s revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.